|

Lonitoclax (ZE50-0134) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Lomond Therapeutics Holdings, Inc.1

Indications

  • Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia1
  • SLL (Small Lymphocytic Lymphoma)1
  • CLL (Chronic Lymphocytic Leukemia)1
  • CLL / SLL1
  • Marginal Zone Lymphoma (MZL)1

Louisville, Kentucky1 trial

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Norton Cancer Institute, St. Matthews Campus

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.